28 Mar, 2024 Publication - Patents: Review of the Year By Dominic Adair Katie Cambrook Brian Cordery Amy Cullen Chloe Dickson Charlie French Matthew Hunt Nicholas Round Jonathan Ross Eden Winlow +7 more... Show less For patent practitioners everywhere, 2023 was a significant year. Ten years after the signing of the international treaty governing its...
25 Mar, 2024 A detailed analysis of the first substantive UPC Court of Appeal decision – lifting a preliminary injunction against NanoString By Eden Winlow NanoString Technologies Inc.; NanoString Technologies Germany GmbH; NanoString Technologies Netherlands B.V. v President and Fellows of...
01 Mar, 2024 MHRA grants first medicine approval via the new International Recognition Procedure By Jamie Hatzel For the very first time, the MHRA has a granted a UK marketing authorisation (UKMA) for a medicine through its new International...
18 Jan, 2024 Publication: Biotech Review of the Year By Gregory Bacon Xisca Borrás Will Hewitt 2023 is likely to be remembered as a year in which a number of highly anticipated developments in the biotech industry finally came to...
25 Sep, 2023 MHRA simplifies legal representative requirements for clinical investigations in Northern Ireland By Jamie Hatzel Since Brexit, the UK has been subject to two separate regulatory frameworks on medical devices. Great Britain is subject to the Medical...
31 Aug, 2023 A Turing Test for Embryos? By Bristows Philip Ball writes on an important contribution to the discussion on the twilit zone between human embryo models and actual human...
11 Jul, 2023 Curtain raised on New Genomic Techniques Regulation By Bristows European Commission proposes to ease the regulatory burden for gene-edited plants. But when will it become law, and in what form? The...
05 Jul, 2023 Spin-out trends: Views from the PraxisAuril conference By Erik Müürsepp Last month Adam Coughlin and Erik Müürsepp from Bristows’ Commercial IP team had the opportunity to attend the annual conference of...
29 Jun, 2023 “Synthetic Embryos”: What's in a name? By Bristows "Synthetic Embryos" are neither Synthetic nor Embryos. So why are editors giving that name to stem cell-based models of human...
25 May, 2023 BioIntegrates 2023: Biotech pinch points and strategic decisions By Ellen Lambrix Ellen Lambrix and Adam Coughlin from Bristows' Commercial IP team attended the BioIntegrates conference in London on 16 May 2023. With...
27 Mar, 2023 Cell and gene therapy platforms licensing – exclusivity and carving-up fields By Louisa Jacobs Cell and gene therapies (CGTs) are highly complex and sophisticated technologies with a lot of constituent parts. To bring a product to...
01 Mar, 2023 Consultation on the Reform of the Human Fertilisation & Embryology Act Regulating Scientific Advance By Bristows This HFEA consultation, launched on Tuesday, is important not only for IVF clinics, but to all those working in the fields of...